Drug Trial Radar · NCT07314567
ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (SLE)
Last checked: Nov 19, 2026Latest source record: Jan 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
22
Planned (sponsor's estimate)
Start
Jan 1, 2026
Primary completion
Oct 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Tongji HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 2, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment in subjects with Relapsed/Refractory Systemic lupus erythematosus (SLE)
Conditions
- System Lupus Erythematosus(SLE)
Interventions
ACE1831Drug
ACE1831 is allogeneic gamma delta T (gdT) cell therapy. Subjects will receive ACE1831 dose based on the assigned dose escalation cohort.
Lymphodepleting chemotherapyDrug
Subjects assigned to receive lymphodepleting preconditioning (LDC) will receive chemotherapy cyclophosphamide ahead of ACE1831 administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the safety and tolerability of ACE1831 in subjects with Refractory Systemic lupus erythematosusTime frame: 24 weeks after last dose of ACE1831
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tongji Hospital
Wuhan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.